Michael Sebastian

3.7k total citations
57 papers, 1.4k citations indexed

About

Michael Sebastian is a scholar working on Dermatology, Immunology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Michael Sebastian has authored 57 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Dermatology, 23 papers in Immunology and 12 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Michael Sebastian's work include Psoriasis: Treatment and Pathogenesis (17 papers), Dermatology and Skin Diseases (16 papers) and Autoimmune Bullous Skin Diseases (6 papers). Michael Sebastian is often cited by papers focused on Psoriasis: Treatment and Pathogenesis (17 papers), Dermatology and Skin Diseases (16 papers) and Autoimmune Bullous Skin Diseases (6 papers). Michael Sebastian collaborates with scholars based in Germany, United States and Canada. Michael Sebastian's co-authors include Kristian Reich, Thomas Ruzicka, Helen Mann, H. Akamatsu, Yi‐Long Wu, Diamant Thaçi, Serban Ghiorghiu, Ulrich Mrowietz, Alison Templeton and Kenneth J. O’Byrne and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Journal of the American Academy of Dermatology.

In The Last Decade

Michael Sebastian

54 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Michael Sebastian Germany	20	734	382	360	330	210	57	1.4k
M.F. Mohd Mustapa United Kingdom	21	665 0.9×	105 0.3×	409 1.1×	157 0.5×	42 0.2×	54	1.7k
Tamara Salam Housman United States	16	981 1.3×	45 0.1×	270 0.8×	327 1.0×	135 0.6×	31	1.5k
Giuseppe Menna Italy	18	226 0.3×	88 0.2×	155 0.4×	126 0.4×	239 1.1×	49	1.0k
Jonathan S. Leventhal United States	20	374 0.5×	138 0.4×	290 0.8×	718 2.2×	19 0.1×	84	1.5k
Colin Fleming United Kingdom	20	810 1.1×	28 0.1×	490 1.4×	243 0.7×	157 0.7×	53	1.3k
Peter Häusermann Switzerland	22	467 0.6×	72 0.2×	312 0.9×	133 0.4×	69 0.3×	49	1.1k
Rainer Rompel Germany	20	691 0.9×	43 0.1×	208 0.6×	543 1.6×	35 0.2×	78	1.5k
Kara N. Shah United States	14	291 0.4×	52 0.1×	434 1.2×	85 0.3×	37 0.2×	28	860
A. Pérez‐Ferriols Spain	15	406 0.6×	42 0.1×	217 0.6×	60 0.2×	90 0.4×	100	709
M. Vincent United States	14	170 0.2×	170 0.4×	301 0.8×	1.5k 4.7×	22 0.1×	28	2.2k

Countries citing papers authored by Michael Sebastian

Since Specialization

Citations

This map shows the geographic impact of Michael Sebastian's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Sebastian with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Sebastian more than expected).

Fields of papers citing papers by Michael Sebastian

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Sebastian. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Sebastian. The network helps show where Michael Sebastian may publish in the future.

Co-authorship network of co-authors of Michael Sebastian

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Sebastian. A scholar is included among the top collaborators of Michael Sebastian based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Sebastian. Michael Sebastian is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Gold, Linda Stein, Michael Sebastian, Brandon Becker, et al.. (2025). Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 (TYK2) Inhibitor, in Patients with Moderate to Severe Scalp Psoriasis: Time to Meaningful Improvement in Patient-Reported Outcomes in a Phase 3b/4, Multicenter, Randomized, Double-blinded, Placebo-Controlled Study (PSORIATYK SCALP). SKIN The Journal of Cutaneous Medicine. 9(2). s533–s533.

Harris, John E., Kim Papp, Khaled Ezzedine, et al.. (2025). Open-label treatment extension of ruxolitinib cream in vitiligo: findings from the Topical Ruxolitinib Evaluation in Vitiligo (TRuE-V) long-term extension phase III study. British Journal of Dermatology. 194(3). 591–593. 1 indexed citations

Thaçi, Diamant, Andreas Pinter, Michael Sebastian, et al.. (2023). Guselkumab demonstrates long-term efficacy and maintenance of treatment response postwithdrawal in systemic treatment-naïve patients and nonresponders to fumaric acid esters: results from parts II and III of a randomized active-comparator-controlled phase IIIb trial (POLARIS). British Journal of Dermatology. 191(1). 36–48. 1 indexed citations

Augustin, Matthias, Claudia Zeidler, Ralph von Kiedrowski, et al.. (2023). Indikation zur Systemtherapie bei chronischer Prurigo: Kommentierte Checkliste für die Praxis. JDDG Journal der Deutschen Dermatologischen Gesellschaft. 21(7). 822–824. 2 indexed citations

Bulfone, Giampiera, Paolo Iovino, Michael Sebastian, et al.. (2022). Self‐efficacy, burnout and academic success in nursing students: A counterfactual mediation analysis. Journal of Advanced Nursing. 78(10). 3217–3224. 31 indexed citations

Solish, Nowell, Benjamin Ascher, Rui L. Avelar, et al.. (2022). PrabotulinumtoxinA vs OnabotulinumtoxinA for the Treatment of Adult Males With Moderate to Severe Glabellar Lines: Post-hoc Analyses of the Phase III Clinical Study Data. Aesthetic Surgery Journal. 42(12). 1460–1469. 7 indexed citations

Guenther, Lyn, et al.. (2022). Impact of fixed‐dose combination Cal/BD foam on the work productivity of patients with psoriasis: results from the 52‐week randomized, double‐blind, PSO‐LONG trial. Journal of the European Academy of Dermatology and Venereology. 36(7). 1054–1063. 1 indexed citations

Thaçi, Diamant, Kilian Eyerich, Andreas Pinter, et al.. (2021). Direct comparison of risankizumab and fumaric acid esters in systemic therapy–naïve patients with moderate-to-severe plaque psoriasis: a randomized controlled trial. British Journal of Dermatology. 186(1). 30–39. 15 indexed citations

Mok, Tony, Yi‐Long Wu, M. Ahn, et al.. (2017). Osimertinib or platinum–pemetrexed in EGFR T790M–positive lung cancer. QUT ePrints (Queensland University of Technology). 290 indexed citations

10.

Sebastian, Michael, et al.. (2016). Blunt traumatic tension chylothorax: Case report and mini-review of the literature. World Journal of Clinical Cases. 4(11). 380–380. 8 indexed citations

11.

Bissonnette, Robert, David M. Pariser, Norman Wasel, et al.. (2016). Apremilast, an oral phosphodiesterase-4 inhibitor, in the treatment of palmoplantar psoriasis: Results of a pooled analysis from phase II PSOR-005 and phase III Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis (ESTEEM) clinical trials in patients with moderate to severe psoriasis. Journal of the American Academy of Dermatology. 75(1). 99–105. 61 indexed citations

12.

Schaller, Martin, Michael Sebastian, Claudia Ress, D. Seidel, & Michael Hennig. (2016). A multicentre, randomized, single‐blind, parallel‐group study comparing the efficacy and tolerability of benzoyl peroxide 3%/clindamycin 1% with azelaic acid 20% in the topical treatment of mild‐to‐moderate acne vulgaris. Journal of the European Academy of Dermatology and Venereology. 30(6). 966–973. 22 indexed citations

13.

Lynde, Charles, F. Cambazard, Thomas Ruzicka, et al.. (2012). Extended treatment with oral alitretinoin for patients with chronic hand eczema not fully responding to initial treatment. Clinical and Experimental Dermatology. 37(7). 712–717. 22 indexed citations

14.

Szeimies, Rolf‐Markus, Peter Radny, Michael Sebastian, et al.. (2010). Photodynamic therapy with BF-200 ALA for the treatment of actinic keratosis: results of a prospective, randomized, double-blind, placebo-controlled phase III study. British Journal of Dermatology. 163(2). 386–394. 86 indexed citations

15.

Gollnick, Harald, Ulrike Blume‐Peytavi, Georg Popp, et al.. (2010). Systemic isotretinoin in the treatment of rosacea – doxycycline‐ and placebo‐controlled, randomized clinical study. JDDG Journal der Deutschen Dermatologischen Gesellschaft. 8(7). 505–514. 86 indexed citations

16.

Mrowietz, Ulrich, Christophe Klein, Kristian Reich, et al.. (2009). Cyclosporine therapy in dermatology. JDDG Journal der Deutschen Dermatologischen Gesellschaft. 7(5). 474–478. 17 indexed citations

17.

Nast, Alexander, Matthias Augustin, Wolf‐Henning Boehncke, et al.. (2009). S3‐Leitlinie zur Therapie der Psoriasis vulgaris – Update: „Übersicht der Therapieoptionen” und „Efalizumab”. JDDG Journal der Deutschen Dermatologischen Gesellschaft. 8(1). 65–66. 5 indexed citations

18.

Peserico, Andrea, et al.. (2008). Reduction of relapses of atopic dermatitis with methylprednisolone aceponate cream twice weekly in addition to maintenance treatment with emollient: a multicentre, randomized, double-blind, controlled study. British Journal of Dermatology. 158(4). 801–807. 98 indexed citations

19.

Dirschka, Thomas, Uwe Reinhold, Thomas Rosenbach, et al.. (2006). Efalizumab‐Therapie der mittelschweren bis schweren Plaque‐Psoriasis in der Hautarztpraxis. JDDG Journal der Deutschen Dermatologischen Gesellschaft. 4(s1). S3–S12.

20.

Hefny, Ashraf F., et al.. (2005). Actinomycosis of the Gallbladder: Case Report and Review of the Literature. Asian Journal of Surgery. 28(3). 230–232. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact